TABLE II.

Canadian landscape of PD-1/PD-L1 inhibitors in non-small-cell lung cancer (NSCLC)

Drug	Indication	Approvals		Provincial funding
		Health Canada	pCODR
Atezolizumab	Locally advanced or metastatic NSCLC with progression on or after systemic chemotherapy	6 Apr 2018	Under review	Not applicable
Nivolumab	Locally advanced or metastatic NSCLC with progression on or after systemic chemotherapy	26 Feb 2016	3 Jun 2016	Funded: BC, AB, SK, MB, ON, NS, NB, NL Under review: PEI
Pembrolizumab	Previously untreated metastatic NSCLC with tumour expression of PD-L1 and without sensitizing EGFR mutation or ALK translocation. Funding requested for TPS of PD-L1 ≥50%.	12 Jul 2017	23 Aug 2017	Funded: SK, MB, ON Under review: BC, AB, NS, NB, NL, PEI
Pembrolizumab	For treatment of metastatic NSCLC with tumour expression of PD-L1 and previous progression on or after systemic chemotherapy. Funding requested for TPS of PD-L1 ≥1%.	15 Apr 2016	3 Nov 2016	Funded: SK, MB, ON Under review: BC, AB, NS, NB, NL, PEI

TPS = tumour proportion score.